Carotegrast methyl - EA Pharma

Drug Profile

Carotegrast methyl - EA Pharma

Alternative Names: AJM 300

Latest Information Update: 07 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ajinomoto
  • Developer EA Pharma
  • Class Anti-inflammatories; Quinazolines; Small molecules
  • Mechanism of Action Integrin alpha4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Ulcerative colitis
  • No development reported Crohn's disease

Most Recent Events

  • 07 Sep 2017 Phase-III development for Ulcerative colitis is ongoing in Japan (PO) (EA Pharma pipeline, September 2017)
  • 10 Jun 2016 Chemical structure information added
  • 31 Mar 2015 Ajinomoto Pharmaceuticals and Kissei Pharmaceutical agree to co-develop and commercialise carotegrast methyl in Japan for Ulcerative colitis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top